SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Revolution Medicines Presents Pancreatic Cancer Survival Data at ESMO 2026

Revolution Medicines presented overall survival data for daraxonrasib across subgroups in previously treated metastatic pancreatic cancer at ESMO 2026.

RVMD

Related stories